Source:http://linkedlifedata.com/resource/pubmed/id/21640634
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2011-6-27
|
pubmed:abstractText |
To assess the expression of IGF-1R in oral cavity squamous cell carcinoma patients, to explore its relation with clinical and pathologic prognostic factors and its role in predicting clinical outcome. One hundred and thirty-one consecutive patients suffering from oral cavity squamous cell carcinoma were included in this study from July 1989 to April 2005. Follow-up was closed in May 2010. The mean follow-up for survivors was 110.26±47.42 months. Patients were staged following the TNM classification. Patients in tumour stages I and II were referred to surgery. Patients in stages III-IV were referred to postoperative radiotherapy. Radiation therapy was administered up to a mean dose of 62.13±7.74 Gy in 1.8-2 Gy fractions. IGF-1R expression was studied by immunohistochemistry in paraffin-embedded tumour tissue. IGF-1R was expressed in 101 patients (77.1%). IGF-1R expression was related to tumour grade (P=0.012). Tumour stage was the most important prognostic factor for survival. Low (negative and fairly) IGF-1R tumour expression was correlated to better long-term Local Disease Free Survival (P=0.016), Disease-Free Survival (P=0.029), and Survival (P=0.009) in patients achieving tumour stages III-IV. Low IGF-1R expression was related to better long-term control in patients suffering locally advanced oral carcinoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1368-8375
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
pubmed:issnType |
Print
|
pubmed:volume |
47
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
615-9
|
pubmed:meshHeading |
pubmed-meshheading:21640634-Adult,
pubmed-meshheading:21640634-Aged,
pubmed-meshheading:21640634-Aged, 80 and over,
pubmed-meshheading:21640634-Carcinoma, Squamous Cell,
pubmed-meshheading:21640634-Combined Modality Therapy,
pubmed-meshheading:21640634-Female,
pubmed-meshheading:21640634-Humans,
pubmed-meshheading:21640634-Immunohistochemistry,
pubmed-meshheading:21640634-Male,
pubmed-meshheading:21640634-Middle Aged,
pubmed-meshheading:21640634-Mouth Neoplasms,
pubmed-meshheading:21640634-Neoplasm Recurrence, Local,
pubmed-meshheading:21640634-Prognosis,
pubmed-meshheading:21640634-Receptor, IGF Type 1,
pubmed-meshheading:21640634-Treatment Outcome,
pubmed-meshheading:21640634-Young Adult
|
pubmed:year |
2011
|
pubmed:articleTitle |
IGF-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma.
|
pubmed:affiliation |
Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Spain.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|